← Back to Search

Belsomra,(suvorexant) for Alcoholism

Phase 2
Waitlist Available
Led By Barbara J. Mason, Ph.D.
Research Sponsored by The Scripps Research Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 hour during cue reactivity session
Awards & highlights

Study Summary

This trial is testing if a drug called suvorexant can decrease craving for alcohol and reduce drinking in people with alcohol dependence.

Eligible Conditions
  • Alcoholism

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to one week following single dose administration
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to one week following single dose administration for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Visual Analog Scale (VAS) Strength of Craving: Combined Arms Conditional Model
Visual Analogue Scale (VAS) of Craving Severity: 2 Arms
Secondary outcome measures
Number of Standard Drinks Per Day: 2 Arms
Number of Standard Drinks Per Day: Combined Arms Conditional Model

Trial Design

2Treatment groups
Active Control
Placebo Group
Group I: Belsomra,(suvorexant)Active Control1 Intervention
20 mg single-dose administration given on an inpatient clinical research unit
Group II: PlaceboPlacebo Group1 Intervention
Placebo single-dose administration given on an inpatient clinical research unit

Find a Location

Who is running the clinical trial?

The Scripps Research InstituteLead Sponsor
30 Previous Clinical Trials
10,556 Total Patients Enrolled
13 Trials studying Alcoholism
917 Patients Enrolled for Alcoholism
National Institute on Alcohol Abuse and Alcoholism (NIAAA)NIH
799 Previous Clinical Trials
1,362,485 Total Patients Enrolled
422 Trials studying Alcoholism
985,182 Patients Enrolled for Alcoholism
Barbara J. Mason, Ph.D.Principal InvestigatorThe Scripps Research Institute
6 Previous Clinical Trials
221 Total Patients Enrolled
5 Trials studying Alcoholism
171 Patients Enrolled for Alcoholism

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the uppermost cap on patient participation in this trial?

"Correct. Evidenced by clinicaltrials.gov, this medical trial is actively recruiting participants and was initially posted on November 17th 2021. 50 prospective patients need to be sourced from a single site for the study to commence."

Answered by AI

Is this research endeavor recruiting participants of advanced age?

"As per the specified criteria, all participants must be 18-65 years of age. There are 20 studies available for minors and another 211 trials dedicated to individuals over 65."

Answered by AI

What qualifications must potential participants possess to qualify for this trial?

"The prerequisites for acceptance into this trial include a diagnosis of alcoholism and an age between 18 to 65. At present, the study is seeking approximately 50 participants."

Answered by AI

Are there any other investigations that have been conducted regarding the efficacy of Belsomra (suvorexant)?

"Currently, 14 clinical studies on Belsomra (suvorexant) are active with two at the Phase 3 stage. 71 medical centres across the United States have trials for this medication and many of them are based in Baltimore, Maryland."

Answered by AI

Is enrollment still available for this experiment?

"Affirmative. As detailed on clinicaltrials.gov, this medical research project was initially advertised in November of 2021 and is presently recruiting participants; 50 patients need to be enrolled from a single site."

Answered by AI

To what degree is Belsomra (suvorexant) a safe remedy for patients?

"Due to limited data surrounding Belsomra's efficacy, our team at Power assigned it a safety score of 2 on a 3-point scale."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
Medication Development in Alcoholism: Suvorexant Versus Placebo
2021. "Medication Development in Alcoholism: Suvorexant Versus Placebo". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04229095.
~8 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top